Learn more about Teva’s efforts to address ESG topics in our 2019 ESG Progress Report.

How we made an impact in 2019

Our Patients

- Expanded portfolio of quality medicines worldwide
- 25...8,000 new innovations, spanning medicines from early-stage research to late-stage development.
- 1,000+...specialty medicines.
- 518+...for research, innovation, and development.

Our People

- 93%...of sites implemented global Environment, Health and Safety Management System.
- 11%...reducible injury rate.
- 23%...low back injury rate.
- 4%...for certain critical business processes.

Our Protocols

- 15,000+...of key ethical behavior topics.
- 140...program.
- 42...under Sarbanes-Oxley Act.
- 3...in 2018.

Our Planet

- Reduced...greenhouse gas emissions by 17% from 2017.
- Reduced...by 7% from 2018.
- Reduced...by 6% from 2018.

Our Performance

- FTSE4Good: 88th percentile for sub-sector.
- ISS Quality Score: 55th percentile, compared to 40th in 2017.

Learn more about Teva’s efforts to address ESG topics in our 2019 ESG Progress Report.